͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
| | There is only one month to go until co-chairs Sarah Blagden, Marc Gunter and Elizabeth Jaffee open this year’s Cancer Prevention Research Conference.
We look forward to welcoming you to London for three days of knowledge-sharing and networking to spark new ideas and collaborations that advance prevention research.
In this year’s jam-packed programme, you will hear new research insights from experts, including: |
| - Jen Morton (Cancer Research UK Scotland Institute) on “Interception opportunities for preneoplastic lesions of pancreatic cancer”
- Tuomas Tammela (Memorial Sloan Kettering Cancer Center) on “Intersection of tumorigenesis and aging-associated decline in lung regenerative potential”
- Seema Khan (Northwestern Feinberg School of Medicine) on “Cancer therapy drugs in the preventive arena: optimizing dose & delivery”
| Head to our website to see the full agenda, with new talk titles confirmed each day.
Don’t have your ticket yet? Register today to join us in London from 25-27 June. |
| |
|
|
|
|
|
| Beyond the genome: harnessing the power of super-enhancers for blood cancer |
| In the search for more precise treatments for blood cancers, Lisa Russell, Senior Lecturer in Childhood Cancer and Haematology at Newcastle University, is turning her attention beyond the genetic code to the epiregulome, the dynamic regulatory networks of the non-coding genome.
At the centre of this research are super-enhancers, powerful regulatory elements that drive the expression of genes involved in cell identity and tumour suppression, safeguarding healthy cells from malignant transformation. However, this ability makes them vulnerable to hijacking by cancer cells.
Lisa has spent the past two decades investigating how super-enhancer reprogramming contributes to oncogenesis, shedding light on the mechanisms that drive their function.
The promise of super-enhancer biology research is vast, offering a pathway to more precise, less toxic therapies that could transform treatment for patients with blood cancers. |
| |
|
|
|
|
|
| | In a two-part podcast series from the European Medical Journal, Jonathan Sackier sits down with Sarah Blagden, Professor of Experimental Oncology and Director of our Clinical Trials Unit in Oxford.
In the first episode, Sarah discusses her path into oncology, her experiences with improving the clinical trials landscape and offers valuable insights into the dysregulation of mRNA translation in cancer and the future of cancer prevention. | |
| | | | In a CRUK-funded study published in Science Translational Medicine, researchers identified CD21, a pan–B cell marker, as a promising new target for treating T-cell acute lymphoblastic leukaemia (T-ALL).
Nicola Maciocia (UCL) and colleagues found that CD21 is expressed in around 50% of T-ALL cases, but in fewer than 10% of mature T cells, making it an attractive candidate for selective targeting.
In preclinical models, anti-CD21 CAR T cells showed potent cytotoxicity and selectivity for T-ALL cells, largely sparing healthy T cells and thereby minimising the risk of T cell aplasia.
These findings point to CD21 as a promising strategy for safer, more effective CAR T-cell therapies to treat T-ALL. | |
|
---|
|
|
|
|
| | Hosted this year by our Scotland Institute, the seventh edition of the Organoids Are Us symposium will bring together basic and clinical researchers to explore the full potential of organoid-based technologies.
You can expect a varied programme of plenaries, keynotes, symposium sessions, rapid-fire talks and posters. Speakers include Hans Clevers, Vivian Li, Fiona Oakley, Mathew Garnett and Tom Bird.
No matter your career stage, you’re invited to join the conversation and contribute to in-depth discussions in this dynamic and rapidly evolving field.
Join the event for four days of innovation, connection and scientific discovery from 23–26 September.
Grab your early bird ticket before 15 June for a discounted rate. |
| |
|
|
|
|
|
| | | | 13:30-14:30, 05 June 2025 |
|
---|
| | | | 12:00-13:00, 16 July 2025 |
|
---|
| | | | 13:30-18:00, 28 October 2025 |
|
---|
|
|
|
|
| Improving the efficiency of clinical trials – from methods to practice |
| How can advanced statistical designs help optimise clinical trials?
Join leading statistical experts for a hybrid workshop hosted by the University of Bath exploring advanced statistical designs to enhance the efficiency and effectiveness of modern clinical trials.
Through a series of engaging talks and interactive sessions, you'll gain insights into the latest developments in statistical trial design, including: |
| - basket and platform trials
- cluster randomised trials
- first-in-human trials
- group sequential and adaptive trials
| The agenda offers practical guidance to researchers, clinicians and statisticians alike on bridging the gap between innovative proposals and real-world applications, while also providing valuable networking opportunities throughout.
This workshop, including the pre-workshop training, will be made free to attend for CRUK-funded researchers. |
| |
|
|
|
|
|
Funding & research opportunities |
| Get in touch with our office for confidential advice on eligibility, remit and funding options prior to applying. |
|
| | | | | | | | | | | | | Applications accepted all year round |
|
---|
|
| |
|
|
| Together we are beating cancer |
| | |
---|
|
|
|
| You are playing a crucial role in helping us beat cancer, so we'd like to continue to keep you updated on what we're up to. You can manage your preferences and unsubscribe here.
Your details are safe with us. Check out our Privacy Policy.
Our supporters are at the heart of everything we achieve at Cancer Research UK. Read our Fundraising Promise.
This email is from Cancer Research UK. Cancer Research UK is a registered charity in England and Wales (1089464), Scotland (SC041666), the Isle of Man (1103) and Jersey (247). A company limited by guarantee. Registered company in England and Wales (4325234) and the Isle of Man (5713F). Registered address: 2 Redman Place, London, E20 1JQ. |
|
|
|